Endovascular Engineering Raises $42 Million in Series B Financing to Advance the Treatment of Pulmonary Embolism

Whats Happening:

Endovascular Engineering, Inc. (E2) has secured $42 million in an oversubscribed Series B financing round to advance its next-generation clot removal technology platform for venous thromboembolism (VTE). The funding will accelerate E2's mission to transform VTE treatment, with an initial focus on advancing novel solutions for addressing Pulmonary Embolism (PE).

Key Moves:

• E2 secures $42 million in Series B financing

• Funding to advance clot removal technology for VTE treatment

• Initial focus on novel solutions for Pulmonary Embolism

By The Numbers:

• $42 million raised in Series B financing

• 415 Capital manages nearly $200 million in assets

• S3 Ventures has $900M+ in assets under management

Key Quotes:

• "This financing represents more than capital – it validates our technology platform and positions us to revolutionize PE treatment," said E2's CEO Dan Rose.

• "E2 is developing a best-in-class therapy for PE, the third leading cause of cardiovascular death," said Dr. Ruben Osnabrugge, Partner at 415 Capital.

• "We are truly impressed by E2's next-generation platform technology for VTE and see this as a solution to dramatically scale the mechanical thrombectomy market and improve the lives of patients," said Brian R. Smith, Managing Director at S3 Ventures.

Bottom Line:

Endovascular Engineering's successful Series B funding round positions the company to advance its innovative clot removal technology for VTE treatment, particularly focusing on Pulmonary Embolism. With strong investor support and a promising technology platform, E2 is poised to potentially revolutionize PE treatment and establish a new standard of care in interventional medicine.

Read Full Article